CJC-1295 No DAC (5mg Vial) Dosage Protocol
Short-acting GHRH analog (Modified GRF 1-29) — research/educational dosing reference.
Mix & measure CJC-1295 NO DAC · 5 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Quickstart Highlights
CJC-1295 without DAC (also called Modified GRF 1-29 or mod GRF) is a lab-made growth-hormone-releasing hormone (GHRH) analog. Unlike the DAC version, it does not bind serum albumin, so its half-life is only about 30 minutes and it triggers a brief, pulse-like release of growth hormone that closely mimics the body’s natural rhythm[1][2]. Because it is short-acting, it is injected more frequently — commonly ~100 mcg one to three times per day (for example before bed and post-workout). This educational page outlines a daily subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. It is an unapproved research chemical, not a medicine: clinical development was abandoned and there are no controlled human efficacy trials for body composition, performance, or anti-aging — presented for research and educational use only.
Add 3.0 mL bacteriostatic water to one 5 mg vial → ~1.67 mg/mL (1,670 mcg/mL), a practical dilution for accurate dosing.
100–300 mcg per injection, once daily (often dosed before bed), titrated upward gradually because the No-DAC version is short-acting.
At 1.67 mg/mL, 1 unit ≈ 16.7 mcg (0.01 mL); 100 mcg ≈ 6 units and 300 mcg ≈ 18 units on a U-100 syringe (units = dose ÷ 1.67 mg/mL).
Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); once reconstituted, refrigerate and use within 1–2 weeks, or freeze at ≤−20 °C for longer storage.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Dosing & Reconstitution Guide
A single practical dilution with accurate once-daily dosing, step by step
Standard / Gradual Approach (3 mL = ~1.67 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 5 mg vial → final concentration ~1.67 mg/mL (1,670 mcg/mL).
Typical daily range: 100–300 mcg once daily, raised gradually over an 8–12 week course.
Easy measuring: At 1.67 mg/mL, 1 unit ≈ 16.7 mcg (0.01 mL) on a U-100 syringe. Units = dose (mcg) ÷ 16.7, so 100 mcg lands at ~6 units (0.06 mL).
Storage: Lyophilized: refrigerate at 2–8 °C (35.6–46.4 °F); after reconstitution, refrigerate and use within 1–2 weeks, or freeze at ≤−20 °C for longer storage.
Frequency: one subcutaneous injection per day, typically at bedtime to align with the body’s natural nocturnal GH pulse. Because the No-DAC form is short-acting (~30-minute half-life), it is dosed daily — and is often split into 1–3 smaller injections per day (e.g. before bed and post-workout)[1][2]. For very small volumes (≤0.10 mL), a 30- or 50-unit insulin syringe improves readability. These figures come from reference protocols, not from approved human dosing.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution gives ~1.67 mg/mL, where each 1-unit mark equals about 16.7 mcg. Refrigerate the reconstituted solution and use it within 1–2 weeks; for longer storage, aliquot and freeze.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Quantities below assume an 8–16 week daily protocol with gradual titration.
At ~1.67 mg/mL and 100–300 mcg daily, a 5 mg vial lasts roughly 2–4 weeks before potency declines, so daily dosing uses more vials than long-acting peptides.
- 8 weeks: ~2 vials
- 12 weeks: ~4 vials
- 16 weeks: ~6 vials
- Per week (1/day): 7 syringes
- 8 weeks: ~56 syringes
- 16 weeks: ~112 syringes
Use ~3.0 mL per 5 mg vial for reconstitution.
- 8 weeks (2 vials): ~6 mL → 1 bottle
- 16 weeks (6 vials): ~18 mL → 2 bottles
One for the vial stopper + one for the injection site each day.
- Per day: 2 swabs
- 8 weeks (1/day): ~112 swabs → 2 boxes
Protocol Overview
A concise summary of the once-daily regimen, drawn from commonly cited reference protocols.
- ▪Goal: Drive brief, pulse-like releases of GH that mimic natural rhythm and raise IGF-1 over time for research into the GH axis — an effect characterized in GHRH pharmacology but never validated for body composition or performance in controlled human trials[1][2].
- ▪Schedule: Once-daily subcutaneous injections (often at bedtime) for 8–12 weeks, optionally extended to ~16 weeks.
- ▪Dose Range: 100–300 mcg daily with gradual titration.
- ▪Reconstitution: 3.0 mL bacteriostatic water per 5 mg vial gives ~1.67 mg/mL for accurate unit measurements.
- ▪Storage: Refrigerate the dry vial at 2–8 °C; once mixed, refrigerate and use within 1–2 weeks, or freeze at ≤−20 °C for longer storage.
Dosing Protocol
A suggested once-daily titration approach based on common reference doses.
- ▪Start: Begin at 100 mcg once daily to gauge tolerability.
- ▪Titrate: Increase by roughly 50 mcg every two weeks as tolerated.
- ▪Target: Reach about 200–300 mcg daily by weeks 5–10.
- ▪Frequency: Once per day; the short half-life means levels do not carry over between doses, so daily (or split daily) administration is used.
- ▪Timing: Inject at a consistent time — bedtime aligns with the natural nocturnal GH pulse — and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Store the dry vial at 2–8 °C (35.6–46.4 °F) in dry, dark conditions; stable for days to weeks at room temperature, but refrigeration extends shelf life[6].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 1–2 weeks for maximal potency; for longer storage, aliquot and freeze at ≤−20 °C[7].
- ▪Handling: Let chilled or frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[5].
- ▪Short-acting profile: Because the No-DAC version clears quickly (~30-minute half-life), it is dosed daily (sometimes split into 1–3 doses) rather than weekly; keep a consistent daily schedule rather than stacking large single doses.
- ▪Recordkeeping: Log each dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: CJC-1295 is a GH-axis agent prohibited by WADA for athletic use and is not FDA-approved for human administration; its clinical development was abandoned[8].
How This Works
CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH). It binds GHRH receptors on the pituitary’s somatotroph cells and signals them to release growth hormone (GH)[3].
The No-DAC version (Modified GRF 1-29) is a truncated GHRH analog with four amino-acid substitutions that improve stability against enzymatic breakdown, but — unlike the DAC form — it does not bind serum albumin. As a result its half-life is only about 30 minutes[1]. This is the key difference: instead of a sustained “GH bleed,” it produces a brief, pulse-like release of GH that closely mimics the body’s natural rhythm, which is why it is injected more frequently (typically once daily, sometimes 1–3 times per day). GHRH-analog pharmacology documents short, dose-dependent increases in GH and IGF-1[1][2].
In research settings CJC-1295 without DAC is frequently paired with a ghrelin-receptor agonist such as Ipamorelin, which acts on a separate receptor to amplify each GH pulse. IGF-1, produced mainly in the liver in response to GH, is the downstream mediator of most GH-axis effects[4].
Important caveat: the early human pharmacology measured only hormone levels, not clinical outcomes. Clinical development was abandoned, and there are no controlled human efficacy trials for body composition, athletic performance, or anti-aging. A sustained, non-physiological elevation of GH and IGF-1 also has an unestablished long-term safety profile, and chronically high IGF-1 is a recognized theoretical concern. Popular claims about muscle gain, fat loss, and recovery should be read as hypotheses, not established facts.
CJC-1295 without DAC is not an approved medicine. It is an unapproved research chemical presented here for research and educational purposes only.
Lifestyle Factors
Habits often discussed alongside GH-axis research protocols.
- ▪Nutrition: Keep protein intake adequate to support tissue maintenance; tailor energy intake to research goals.
- ▪Activity & rest: Pair appropriate resistance and aerobic work with genuine recovery time.
- ▪Sleep: Aim for 7–9 hours; the body’s own largest GH pulse occurs during deep sleep[4].
- ▪Stress: Manage stress with evidence-based practices, since it influences hormonal balance.
Potential Benefits & Side Effects
What the limited literature describes; outcomes in humans are not established and individual results vary.
Reported / Hypothesized Effects
- ▪GH / IGF-1 elevation (measured): GHRH-analog pharmacology shows brief, pulse-like, dose-dependent rises in GH and IGF-1[1].
- ▪Body-composition claims (unproven): Lean-mass and fat-loss benefits are inferred from GH-axis biology but have not been demonstrated for CJC-1295 in controlled human trials.
- ▪Pharmacokinetics: The short ~30-minute half-life of the No-DAC form is well characterized and underlies the frequent (daily) dosing[1].
- ▪Note on evidence: No completed efficacy trials exist; development was abandoned, so all performance and anti-aging benefits remain unestablished[2].
Possible Side Effects
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪GH-related effects: Transient flushing, headache, tingling, or fluid retention are described, consistent with raised GH/IGF-1.
- ▪Unknown long-term profile: Sustained, non-physiological GH/IGF-1 elevation has unestablished long-term safety; chronically high IGF-1 is a theoretical concern.
- ▪Sport restriction: GHRH analogs including CJC-1295 are WADA-prohibited for athletes.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[5][10].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[10].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[5].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[5].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each time to prevent irritation and lipohypertrophy[5].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
J Clin Endocrinol Metab (2006) — Teichman SL et al.Prolonged stimulation of GH and IGF-1 secretion by CJC-1295, a long-acting albumin-bound GHRH analog, in healthy adults.
- 2
J Clin Endocrinol Metab (2006) — Ionescu M, Frohman LAPulsatile GH secretion persists during continuous CJC-1295 stimulation, but the net effect is a sustained, non-pulsatile rise in GH and IGF-1.
- 3
Am J Physiol Endocrinol Metab (2006) — Alba M et al.Once-daily CJC-1295 (a GHRH analog) normalizes growth in a GHRH-knockout mouse model — mechanistic GHRH-receptor activation.
- 4
StatPearls (NCBI Bookshelf) — Brinkman JE et al.Physiology, Growth Hormone — GH/IGF-1 axis, pulsatile secretion, and downstream signalling.
- 5
CDC Pink Book (Chapter 6)Vaccine administration: subcutaneous route — angle, site, and no-aspiration guidance.
- 6
Peptide Storage Guide (GenScript)Best practices for storing lyophilized peptides (temperature, humidity and light protection).
- 7
Bacteriostatic Water GuidanceBacteriostatic water for injection: multi-dose vial stability and handling.
- 8
WADA Prohibited ListGrowth-hormone secretagogues and GHRH analogs (including CJC-1295) are prohibited substances in competitive sport.
- 9
Postgrad Med J (2006) — Ayuk J, Sheppard MCGrowth hormone and its disorders — physiology and risks of GH/IGF-1 excess.
- 10
Johns Hopkins Arthritis CenterHow to give a subcutaneous injection — patient guidance on technique and site rotation.
How to reconstitute CJC-1295 NO DAC
- 1Wipe the vial stopper and your bacteriostatic-water vial with an alcohol swab.
- 2Draw your chosen amount of bacteriostatic water and inject it slowly down the inner wall of the CJC-1295 NO DAC vial.
- 3Let it rest, then gently swirl until fully dissolved — do not shake.
- 4Refrigerate the reconstituted vial and draw each dose with a U-100 insulin syringe.
CJC-1295 NO DAC — frequently asked questions
How do I reconstitute a 5 mg vial of CJC-1295 NO DAC?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to CJC-1295 NO DAC?
There is no single correct amount — more water simply spreads the same 5 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store CJC-1295 NO DAC after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 5 mg vial of CJC-1295 NO DAC provide?
Divide the vial strength of 5 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is CJC-1295 NO DAC approved for human use?
No. CJC-1295 NO DAC is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.